Succinimide hydroxamic acids as potent inhibitors of histone deacetylase (HDAC)

Bioorganic and Medicinal Chemistry Letters

Volumn 12, Issue 20, 2002, Pages 2919-2923

  Curtin, Michael L ^a   Garland, Robert B ^a   Heyman, H Robin ^a   Frey, Robin R ^a   Michaelides, Michael R ^a   Li, Junling ^a   Pease, Lori J ^a   Glaser, Keith B ^a   Marcotte, Patrick A ^a   Davidsen, Steven K ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HISTONE DEACETYLASE; MACROCYCLIC COMPOUND; SUCCINIMIDE DERIVATIVE; SUCCINIMIDE HYDROXAMIC ACID; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; ASSAY; CELL PROLIFERATION; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; ENZYME INHIBITION; IN VITRO STUDY; TUMOR CELL;

AMINO ACIDS; ANTINEOPLASTIC AGENTS; BINDING SITES; CRYSTALLOGRAPHY, X-RAY; ENZYME INHIBITORS; HISTONE DEACETYLASES; HUMANS; HYDROXAMIC ACIDS; INDICATORS AND REAGENTS; K562 CELLS; MOLECULAR CONFORMATION; STRUCTURE-ACTIVITY RELATIONSHIP; SUCCINIMIDES; TUMOR CELLS, CULTURED;

EID: 18644362147     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(02)00622-4     Document Type: Article

References (28)

1. (a) Cheung, W. L.; Briggs, S. D.; Allis, C. D. Curr. Opin. Cell Biol. 2000, 12, 326
2. (b) Cress W.D., Seto E. J. Cell. Physiol. 184:2000;1.
3. Coombes R.C., Vigushin D.M. Anti-Cancer Drugs. 13:2002;1.
4. (a) Gray, S. G.; Ekstrom, T. J. Exp. Cell. Res. 2001, 262, 75.
5. (b) For a discussion of the SIRT active site, see: Dutnall R.N., Pillus L. Cell. 105:2001;161.
6. For the most recent published isolation (HDAC 10), see: Kao H.Y., Lee C.H., Komarov A., Han C.C., Evans R.M. J. Biol. Chem. 277:2002;187.
7. (a) Jung M. Curr. Med. Chem. 8:2001;1505
8. (b) Meinke P.T., Liberator P. Curr. Med. Chem. 8:2001;211.
9. 50 was determined using immunoprecipitated HDAC1. Richon V.M., Emiliani S., Verdin E., Webb Y., Breslow R., Rifkind R.A., Marks P.A. Proc. Natl. Acad. Sci. U.S.A. 95:1998;3003.
10. 50 was determined in ref 8 against recombinant HDAC1. Kijima M., Yoshida M., Sugita K., Horinouchi S., Beppu T. J. Biol. Chem. 268:1993;22429.
11. 50 was determined using recombinant HDAC1. Furumai R., Komatsu Y., Nishino N., Khochbin S., Yoshida M., Horinouchi S. Proc. Natl. Acad. Sci. U.S.A. 98:2001;87.
12. 18
13. (b) Compound 4 is similar to inhibitors reported in: Jung M.; Hoffmann, K.; Brosch, G.; Loidl, P. Bioorg. Med. Chem. Lett. 1997, 7, 1655.
14. (a) Sternson S.M., Wong J.C., Grozinger C.M., Schreiber S.L. Org. Lett. 3:2001;4239
15. (b) Jung M., Gerald B., Kolle D., Scherf H., Gerhauser C., Loidl P. J. Med. Chem. 42:1999;4669.
16. Steinman D.H., Curtin M.L., Garland R.B., Davidsen S.K., Heyman R.H., Holms J.H., Albert D.H., Magoc T.J., Nagy I.B., Marcotte P.A., Li J., Morgan D.W., Hutchins C., Summers J.B. Bioorg. Med. Chem. Lett. 8:1998;2087.
17. 1H NMR, mass spectroscopy and elemental analysis.
18. An X-ray crystal structure was obtained of carboxylic acid 9, which was isolated in low yield from a macrocycle synthetic route similar to that shown in Scheme 4 . Carboxylic acid 9 was coupled with amine 10 and the product was debenzylated to give authentic hydroxamic acid 6.
19. Cyclizations of succinamide esters under basic conditions have been reported but only for acyclic systems with unhindered esters (i.e., methyl, benzyl). For an example, see: Fujii N., Nomizu M., Futaki S., Otaka A., Funakoshi S., Akaji K., Watanabe K., Yajima H. Chem. Pharm. Bull. 34:1986;864.
20. Beckett R.P., Crimmin M.J., Davis M.H., Spavold Z. Synlett. 1993;137.
21. Bodansky M., Martinez J. J. Org. Chem. 43:1978;3071.
22. Curtin M.L., Garland R.B., Davidsen S.K., Marcotte P.A., Albert D.H., Magoc T.J., Hutchins C. Bioorg. Med. Chem. Lett. 8:1998;1443.
23. Yoshida M., Kijima M., Akita M., Beppu T. J. Biol. Chem. 265:1990;17174.
24. max fluorescence plate reader (Molecular Devices, San Diego, CA, USA). Treated cells were compared to vehicle treated cells to determine growth inhibition.
25. (a) Hyperacetylation of histone H4 was induced in T24 bladder carcinoma cells after 4 h exposure to HDAC inhibitors. Hyperacetylated histone H4 was analyzed by Western blot using an anti-acetylated H4 antibody (UBI, Lake Placid, NY) and 5 μg/lane of acid-extracted nuclear histones
26. waf1/cip1 monoclonal antibody (UBI) and 100 μg/lane of cellular lysate.
27. Sambucetti L.C., Fischer D.D., Zabludoff S., Kwon P.O., Chamberlin H., Trogani N., Xu H., Cohen D. J. Biol. Chem. 274:1999;34940.
28. Finnin M.S., Donigian J.R., Cohen A., Richon V.M., Rifkind R.A., Marks P.A., Breslow R., Pavletich N.P. Nature. 401:1999;188.